Document is current
Any future updates will be listed below
-
Authors
Hanssen, Kimberley M.
Murray, Jayne
Pandher, Ruby
Alfred, Stephanie
Gamble, Laura D.
Brand, Jennifer
Mosmann, Erin
Kusuma, Frances K.
Mak, Crystal
Kearns, Adam
Kamili, Alvin
Atkinson, Caroline
Minchaca, Alexis Z.
Bertoldo, Jean
Ziegler, David S.
Mussai, Francis
Cheng, Paul N. M.
Norris, Murray D.
Fletcher, Jamie I.
Haber, Michelle
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (2019056)
National Health and Medical Research Council (APP1016699)
National Health and Medical Research Council (APP1016699)
Cancer Institute NSW (TPG2037)
Cancer Institute NSW (14/TPG/1-13)
Cancer Institute NSW (14/TPG/1-13)
- License Information
-
More Information
Article History
Received: 25 June 2025
Accepted: 4 August 2025
First Online: 14 August 2025
Change Date: 27 August 2025
Change Type: Update
Change Details: The original online version of this article was revised: the authors identified an error in the Supplementary Materials. The Supplementary Figures captions are missing.
Declarations
:
: All animal experiments were approved by the University of New South Wales Animal Care and Ethics Committee according to the Animal Research Act, 1985 (New South Wales) and the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (2013), under approvals 17/53B, 20/25B and 22/145B. Patient-derived models were approved by the Sydney Children’s Hospital Network Human Research Ethics Committee (2020/ETH01981).
: Not applicable.
: PNMC is a co-founder and employee of Bio-Cancer Treatment International Ltd. DSZ reports consulting/advisory board fees from Medison Pharma and Roche, and research support from Accendatech.
